30 September 2019 - Geron Corporation today announced that the United States FDA has granted fast track designation to imetelstat for the treatment of adult patients with intermediate-2 or high-risk myelofibrosis whose disease has relapsed after or is refractory to janus kinase inhibitor treatment, or relapsed/refractory myelofibrosis. 

The fast track designation includes patients with primary myelofibrosis (MF) and MF developed after essential thrombocythemia or polycythemia vera. This is the same patient population that was studied in Geron’s IMbark Phase 2 clinical trial. There are currently no marketed drugs specifically approved for relapsed/refractory MF, representing a significant unmet medical need. 

Geron plans to conduct an End of Phase 2 meeting with the FDA by the end of the first quarter of 2020 to determine if there is a regulatory path forward for imetelstat in relapsed/refractory MF.

Read Geron Corporation press release